KLARIA PHARMA HOLDING AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.289 SEK | -1.70% |
|
+44.50% | -37.45% |
| Sales 2023 | - | Sales 2024 * | 88.7M 8.15M | Capitalization | 30.78M 2.83M |
|---|---|---|---|---|---|
| Net income 2023 | -35M -3.22M | Net income 2024 * | 46M 4.23M | EV / Sales 2023 | - |
| Net Debt 2023 | 26.87M 2.47M | Net cash position 2024 * | 30M 2.76M | EV / Sales 2024 * | 0.01 x |
| P/E ratio 2023 |
-1.28
x | P/E ratio 2024 * |
1.45
x | Employees | 5 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 69.54% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.70% | ||
| 1 week | +44.50% | ||
| Current month | -15.74% | ||
| 1 month | -3.02% | ||
| 3 months | -55.12% | ||
| 6 months | -44.42% | ||
| Current year | -37.45% |
1 week
0.21
0.30
1 month
0.140.35
Current year
0.140.76
1 year
0.140.78
3 years
0.1413.88
5 years
0.1413.88
10 years
0.1419.45
| Managers | Title | Age | Since |
|---|---|---|---|
Scott Boyer
CEO | Chief Executive Officer | 62 | 14-12-31 |
| Director of Finance/CFO | 75 | - | |
Hans Olivecrona
CTO | Chief Tech/Sci/R&D Officer | 66 | 22-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 55 | 14-12-31 | |
Scott Boyer
CEO | Chief Executive Officer | 62 | 14-12-31 |
Anders Jacobson
BRD | Director/Board Member | 57 | 21-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 0.289 | -1.70% | 363,060 |
| 24-04-23 | 0.294 | +5.38% | 208,669 |
| 24-04-22 | 0.279 | +13.88% | 435,669 |
| 24-04-19 | 0.245 | +2.94% | 49,926 |
| 24-04-18 | 0.238 | +19.00% | 1,061,010 |
Delayed Quote Nasdaq Stockholm, April 24, 2024 at 10:25 am EDT
More quotes
Klaria Pharma Holding AB (publ) is a Sweden-based holding company engaged in the biotechnology and medical research industry. Through its group subsidiaries, the Company is active in developing and commercializing therapeutic drugs and treatment methods in the fields of migraine and pain related to cancer based on a patented drug delivery platform in the form of an alginate-based polymer film, which facilitates rapid and reliable transmucosal absorption via a muco-adhesive film. The Company operates Klaria Pharma AB as a wholly owned subsidiary.
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -37.45% | 2.89M | |
| -1.51% | 105B | |
| +3.22% | 97.5B | |
| +1.86% | 22.19B | |
| -16.53% | 21.33B | |
| -8.49% | 18.68B | |
| -42.33% | 16.6B | |
| -20.09% | 14.52B | |
| +5.47% | 14.09B | |
| +28.85% | 10.99B |
- Stock Market
- Equities
- KLAR Stock
